308 related articles for article (PubMed ID: 15779418)
1. [Characteristic of metformin for treatment of impaired glucose tolerance].
Ishida W; Satoh J
Nihon Rinsho; 2005 Feb; 63 Suppl 2():433-7. PubMed ID: 15779418
[No Abstract] [Full Text] [Related]
2. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Sakamoto N; Tajima N
Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
[No Abstract] [Full Text] [Related]
3. [Diabetes prevention program (metformin)].
Kusaka I; Nagasaka S
Nihon Rinsho; 2005 Feb; 63 Suppl 2():471-7. PubMed ID: 15779424
[No Abstract] [Full Text] [Related]
4. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.
Fontbonne A; Diouf I; Baccara-Dinet M; Eschwege E; Charles MA
Diabetes Metab; 2009 Nov; 35(5):385-91. PubMed ID: 19665415
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic renaissance. Biguanides in type-2 diabetes: metformin].
Neye H
Pharm Unserer Zeit; 2002; 31(3):264-70. PubMed ID: 12071123
[No Abstract] [Full Text] [Related]
6. [Effect of pioglitazone, one of TZDs, on IGT-patients].
Kobayashi M
Nihon Rinsho; 2005 Feb; 63 Suppl 2():462-70. PubMed ID: 15779423
[No Abstract] [Full Text] [Related]
7. [Pathophysiological conditions progressing from impaired glucose tolerance: type 2 diabetes mellitus].
Asakura T; Ito Y
Nihon Rinsho; 2005 Feb; 63 Suppl 2():237-41. PubMed ID: 15779378
[No Abstract] [Full Text] [Related]
8. [Treatment for coronary artery disease patients with impaired glucose tolerance].
Kume A; Miyazaki T; Daida H
Nihon Rinsho; 2005 Feb; 63 Suppl 2():543-7. PubMed ID: 15779438
[No Abstract] [Full Text] [Related]
9. Discordant effects on central obesity, hepatic insulin resistance, and alanine aminotransferase of low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance.
Retnakaran R; Ye C; Hanley AJ; Harris SB; Zinman B
Diabetes Obes Metab; 2012 Jan; 14(1):91-3. PubMed ID: 21812893
[TBL] [Abstract][Full Text] [Related]
10. Pioglitazone for diabetes prevention in impaired glucose tolerance.
DeFronzo RA; Tripathy D; Schwenke DC; Banerji M; Bray GA; Buchanan TA; Clement SC; Henry RR; Hodis HN; Kitabchi AE; Mack WJ; Mudaliar S; Ratner RE; Williams K; Stentz FB; Musi N; Reaven PD;
N Engl J Med; 2011 Mar; 364(12):1104-15. PubMed ID: 21428766
[TBL] [Abstract][Full Text] [Related]
11. Metformin: diamonds are forever.
Papanas N; Maltezos E; Mikhailidis DP
Expert Opin Pharmacother; 2009 Oct; 10(15):2395-7. PubMed ID: 19678795
[TBL] [Abstract][Full Text] [Related]
12. Metformin: a new treatment option for non-insulin-dependent diabetes mellitus.
Goo AK; Carson DS; Bjelajac A
J Fam Pract; 1996 Jun; 42(6):612-8. PubMed ID: 8656173
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.
Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Numao T; Fukuda T; Shimada K; Kario K
Hypertens Res; 2007 Jan; 30(1):23-30. PubMed ID: 17460368
[TBL] [Abstract][Full Text] [Related]
14. [Adverse effect of biguanides].
Yamasaki Y; Kuroda A
Nihon Rinsho; 2002 Sep; 60 Suppl 9():389-92. PubMed ID: 12387023
[No Abstract] [Full Text] [Related]
15. Polycystic ovary syndrome.
Ehrmann DA
N Engl J Med; 2005 Mar; 352(12):1223-36. PubMed ID: 15788499
[No Abstract] [Full Text] [Related]
16. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease.
Omer Z; Cetinkalp S; Akyildiz M; Yilmaz F; Batur Y; Yilmaz C; Akarca U
Eur J Gastroenterol Hepatol; 2010 Jan; 22(1):18-23. PubMed ID: 19667999
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone versus metformin in two rat models of glucose intolerance and diabetes.
Gad MZ; Ehssan NA; Ghiet MH; Wahman LF
Pak J Pharm Sci; 2010 Jul; 23(3):305-12. PubMed ID: 20566445
[TBL] [Abstract][Full Text] [Related]
18. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
[No Abstract] [Full Text] [Related]
19. [Info-Meeting. Pharmacologic prevention of the progression from impaired glucose tolerance to type 2 diabetes: favorable effects of metformin and acarbose].
Scheen AJ
Rev Med Liege; 2001 Oct; 56(10):727-30. PubMed ID: 11765586
[TBL] [Abstract][Full Text] [Related]
20. [The Study TO Prevent Non-Insulin Dependent Diabetes Mellitus trial (acarbose)].
Nishimura R
Nihon Rinsho; 2005 Feb; 63 Suppl 2():478-82. PubMed ID: 15779425
[No Abstract] [Full Text] [Related]
[Next] [New Search]
